Erlotinib Unknown Status Phase 3 Trials for Lung Cancer Non-Small Cell Cancer (NSCLC) Prevention

IndicationsStatusPurposePhase
Unknown StatusPrevention3
clinicaltrials.gov IdentifierTitleDrugs
NCT01158170Prophylactic Cranial Irradiation in Erlotinib/Gefitinib-responders With Non-small Cell Lung Cancer (NSCLC) (RT1001)